Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 0358320130540020106
Korean Journal of Urology
2013 Volume.54 No. 2 p.106 ~ p.110
Efficacy of Alfuzosin After Shock Wave Lithotripsy for the Treatment of Ureteral Calculi
Cho Hee-Ju

Shin Soon-Cheol
Seo Do-Young
Min Dong-Suk
Cho Jeong-Man
Kang Jung-Yoon
Yoo Tag-Keun
Abstract
Purpose: We evaluated the efficacy of alfuzosin for the treatment of ureteral calculi less than 10 mm in diameter after extracorporeal shock wave lithotripsy (ESWL).

Materials and Methods: A randomized, single-blind clinical trial was performed prospectively by one physician between June 2010 and August 2011. A total of 84 patients with ureteral calculi 5 to 10 mm in diameter were divided into two groups. Alfuzosin 10 mg (once daily) and loxoprofen sodium 68.1 mg (as needed) were prescribed to group 1 (n=41), and loxoprofen sodium 68.1 mg (as needed) only was prescribed to group 2 (n=44). The drug administration began immediately after ESWL and continued until stone expulsion was confirmed up to a maximum of 42 days after the procedure.

Results: Thirty-nine of 41 (95.1%) patients in group 1 and 40 of 43 (93.0%) patients in group 2 ultimately passed stones (p=0.96). The number of ESWL sessions was 1.34¡¾0.65 and 1.41¡¾0.85 in groups 1 and 2, respectively (p=0.33). The patients who required analgesics after ESWL were 8 (19.5%) in group 1 and 13 (30.2%) in group 2 (p=0.31). Visual analogue scale pain severity scores were 5.33¡¾1.22 and 6.43¡¾1.36 in groups 1 and 2, respectively (p=0.056). The time to stone expulsion in groups 1 and 2 was 9.5¡¾4.8 days and 14.7¡¾9.8 days, respectively (p=0.005). No significant adverse effects occurred.

Conclusions: The use of alfuzosin in combination with ESWL seems to facilitate stone passage and to reduce the time of stone expulsion but does not affect the stone-free rate.
KEYWORD
Alfuzosin, Lithortripsy, Urolithiasis
FullTexts / Linksout information
   
Listed journal information
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø